Organization
Biotie Therapies Corp.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Biotie Therapies Corp.
... therapy for alcohol dependence therapy. Selincro has been introduced across Europe by Biotie's partner, H. Lundbeck A/S, a Danish pharmaceutical company specializing in central nervous ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... cause actual results to differ materially, including: the ability to complete the Biotie transaction on a timely basis; the ability to realize the benefits anticipated ...
... differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally ...
... Axikin Pharmaceuticals, Inc., Bayer AG, Beech Tree Labs, Inc., Bioneer Corporation, Biotie Therapies Corp., Boehringer Ingelheim GmbH, C4X Discovery Holdings PLC, Carolus Therapeutics, Inc., Cellular ...
... p.m. (EET) ACORDA THERAPEUTICS, INC. GAINS TITLE TO ALL SHARES IN BIOTIE THERAPIES CORP. AND THE SHARES WILL DELIST FROM NASDAQ HELSINKI Acorda Therapeutics, Inc. ...
... HAS CONFIRMED ACORDA THERAPEUTICS, INC.'S REDEMPTION RIGHT REGARDING THE SHARES IN BIOTIE THERAPIES CORP. AND PUBLIC TRADING IN THE SHARES HAS BEEN TERMINATED The Arbitral ...
... PSC. Biotie retains full rights to BTT1023. Turku, 26 August 2016 Biotie Therapies Corp. Antero Kallio For further information, please contact: Virve Nurmi, Biotie Therapies ...
... COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. The Listing Committee of Nasdaq Helsinki Ltd ("Nasdaq Helsinki") has today, ...
... ("Acorda") owns approximately 96.8 percent of all the shares and votes in Biotie (excluding the treasury shares held by Biotie). Acorda has initiated redemption proceedings ...
... SAS, BioArctic Neuroscience AB, Biogen, Inc., Bionature E.A. Ltd., Biopharm GmbH, Biotie Therapies Corp., BrainStorm Cell Therapeutics Inc., CalAsia Pharmaceuticals, Inc., Calico LLC, Cardax Pharmaceuticals, ...
... Acorda's President and CEO. "We are working towards concluding our acquisition of Biotie later this year and excited about the addition of the tozadenant Phase ...
... BIOTIE THERAPIES CORP. INTERIM REPORT July 28, 2016 at 9.00 a.m. Biotie Therapies Corp.'s ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤